Evidence map›Paper›PMID 31409873›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2020

The inhibitory receptor CD94/NKG2A on CD8

Juliette Eugène, Nicolas Jouand, Kathleen Ducoin, Delphine Dansette, Romain Oger, Cécile Deleine, Edouard Leveque, Guillaume Meurette, Juliette Podevin, Tamara Matysiak and 14 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Multimodal cell-cell communication driving CD8Frontiers in immunology · 2025
    Review
  19. Review
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 4 institutions in 1 country.

Juliette Eugène *Service d'Anatomie et Cytologie Pathologiques, Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France.
Nicolas Jouand *CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.
Kathleen DucoinCRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.
Delphine DansetteService d'Anatomie et Cytologie Pathologiques, Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France.
Romain OgerCRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.
Cécile DeleineCRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.
Edouard LevequeCRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.ORCID http://orcid.org/0000-0003-0002-729X
Guillaume MeuretteInstitut des Maladies de l'Appareil Digestif, Oncologie Digestive, Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France.
Juliette PodevinInstitut des Maladies de l'Appareil Digestif, Oncologie Digestive, Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France.
Tamara MatysiakInstitut des Maladies de l'Appareil Digestif, Oncologie Digestive, Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France.
Jaafar BennounaInstitut des Maladies de l'Appareil Digestif, Oncologie Digestive, Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France.
Stéphane BezieauUniversité de Nantes, Faculté de Médecine, Nantes, France.
Christelle VolteauPlateforme de Biométrie, CHU de Nantes, France.
Wassila El Alami ThomasInstitut d'Histopathologie, Nantes, France.
Jerôme ChetrittInstitut d'Histopathologie, Nantes, France.
Olivier KerdraonDépartement de Biologie des Cancers, Institut de Cancérologie de l'Ouest, Nantes, France.
Pierre FourquierService de Chirurgie Viscérale et Digestive, Hôpital privé du Confluent, Nantes, France.
Emilie ThibaudeauService d'Oncologie Chirurgicale, Institut de Cancérologie de l'Ouest, Nantes, France.
Frédéric DumontService d'Oncologie Chirurgicale, Institut de Cancérologie de l'Ouest, Nantes, France.
Jean-François MosnierService d'Anatomie et Cytologie Pathologiques, Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France.
Claire ToquetService d'Anatomie et Cytologie Pathologiques, Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France.
Anne JarryCRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.
Nadine Gervois *CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.
Céline Bossard *Service d'Anatomie et Cytologie Pathologiques, Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France. celine.bossard@chu-nantes.fr.
Centre Hospitalier Universitaire de Nantes · FRInserm · FRInstitut de Cancérologie de l'Ouest · FRHôpital privé du Confluent · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously demonstrated that HLA-E/β2m overexpression by tumor cells in colorectal cancers is associated with an unfavorable prognosis. However, the expression of its specific receptor CD94/NKG2 by intraepithelial tumor-infiltrating lymphocytes, their exact phenotype and function, as well as the relation with the molecular status of colorectal cancer and prognosis remain unknown. Based on a retrospective cohort of 234 colorectal cancer patients, we assessed the expression of HLA-E, β2m, CD94, CD8, and NKp46 by immunohistochemistry on tissue microarray. The expression profile of HLA-E/β2m on tumor cells and the density of tumor-infiltrating lymphocytes were correlated to the clinicopathological and molecular features (Microsatellite status, BRAF and RAS mutations). Then, from the primary tumors of 27 prospective colorectal cancers, we characterized by multiparameter flow cytometry the nature (T and/or NK cells) and the co-expression of the inhibitory NKG2A or activating NKG2C chain of ex vivo isolated CD94

Indexed as

AdultAgedAged, 80 and overAnimalsbeta 2-MicroglobulinBiomarkers, TumorCD8-Positive T-LymphocytesCell Line, TumorCoculture TechniquesColorectal NeoplasmsFemaleHistocompatibility Antigens Class IHLA-E AntigensHumansImmune Checkpoint InhibitorsImmunohistochemistryB2M protein, humanbeta 2-MicroglobulinBiomarkers, TumorHistocompatibility Antigens Class IHLA-E AntigensImmune Checkpoint InhibitorsKLRC1 protein, humanKLRD1 protein, humanNK Cell Lectin-Like Receptor Subfamily CNK Cell Lectin-Like Receptor Subfamily D

Identifiers

PMID31409873
OpenAlexW2968536306

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.